Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.
Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.
Latest From Brian Yang
Early study results show CanSino’s inhaled vaccine for COVID-19 triggered an immune response similar to its injected counterpart.
The US listing of Chinese artificial intelligence, medical records and patient management system company Linkdoc could be derailed, after China issued new data review requirements tightening the oversight of overseas listings of domestic companies.
Both Nasdaq- and Hong Kong-listed shares in Chinese health-related companies have been free falling with heavy volumes, after foreign investors spooked by China's general crackdown on the tech sector rushed to exit. The two-day sell-off shows high uncertainty and investors' anxiety over the regulatory overreach but underlying fundamentals still seem strong.
A new study in over 400 people reignites fears about the apparent low efficacy of Chinese COVID-19 vaccines, especially among the elderly, and adding to the debate around the need for booster shots.
The latest developments around data security and protection signal the need for rigorous implementation of procedures and potential significant cost increases for pharma and other companies operating in China.
There is talk about offering booster shots to people who have already been fully vaccinated against COVID-19 in China and it’s increasingly clear that the mRNA vaccine from BioNTech/Fosun nearing approval could be the answer. Meanwhile, some Asian countries are turning away from Chinese coronavirus vaccines.